Table 3.

Comparison between the findings of the present study and the latest EULAR/PReS recommendations.

The EULAR/PReS recommendations about treatment*	Main items of the recommendations	Our findings	Compliance between recommendation items and our findings
To avoid prolonged systemic GC use for achieving and maintaining the target, the use of IL-1 and IL-6 inhibitors should be prioritised due to high evidence of efficacy.	GC use can be markedly limited, or even avoided.	97.7% treated with GCs.	No concordance in our real-world data.
	Evidences supporting the use of cs DMARDs is scarce.	58.8% treated with csDMARDs.	Partial concordance in our real-world data.
An IL-1 or an IL-6 inhibitor should be initiated as early as possible when the diagnosis is established.	IL-1 and IL-6 inhibitor should be initiated before 3 months from symptoms onset.	6 months to initiate a bDMARD; 22.7% started a bDMARD within the first 3 months.	No concordance in our real-world data.

*Fautrel B, et al. Ann Rheum Dis. 2024;83:1614-1627.